Association of T Gamma Delta-CD16+ Cells and Anti-CMV Immunoglobulins in the Prevention of CMV Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

November 17, 2021

Primary Completion Date

December 19, 2024

Study Completion Date

December 19, 2024

Conditions
Kidney TransplantationCMV Infection
Interventions
DRUG

Cytotect

"The inclusion visit is conducted by the investigating nephrologist and the patient will receive their first infusion of anti-CMV Ig.~Patients with positive CMV serology at transplantation will receive 6 infusions of 100 units per kilogram of body weight every 15 days with the first injection on the day of transplantation, i.e. at visits D0, S2, S4, S6, S8 and S10. CMV infection will be monitored by quantitative PCR on whole blood every week during 3 months and then every 2 weeks until 4 months and then at months 5 and 6, 9 and 12."

Trial Locations (1)

33000

Hopital Pellegrin, Bordeaux

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Biotest

INDUSTRY

lead

University Hospital, Bordeaux

OTHER